bioAffinity Technologies, Inc. (BIAF): Net Income

Annual figures by period end, from SEC filings.

-$14.91M

Year ended 2025-12-31

-$15.19M

Trailing 12 months to 2026-06-30

2021-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$14.91M	n/m	2026-03-16, From 2025-01-01
2024-12-31	-$9.04M	n/m	2026-03-16, From 2024-01-01
2023-12-31	-$7.94M	n/m	2025-03-31, From 2023-01-01
2022-12-31	-$8.15M	n/m	2024-04-01, From 2022-01-01
2021-12-31	-$6.33M	n/a	2023-03-31, From 2021-01-01

Net Income at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
bioAffinity Technologies, Inc. (BIAF)	2025-12-31	-$14.91M	n/m
Absci Corp (ABSI)	2025-12-31	-$115.18M	n/m
Foxo Technologies Inc. (FOXO)	2025-12-31	-$12.43M	n/m
OmniAb, Inc. (OABI)	2025-12-31	-$64.78M	n/m
iSpecimen Inc. (ISPC)	2025-12-31	-$10.49M	n/m
OneMedNet Corp (ONMD)	2025-12-31	-$2.80M	n/m
MaxCyte, Inc. (MXCT)	2025-12-31	-$44.63M	n/m
Cannabis Bioscience International Holdings, Inc. (CBIH)	2025-05-31	-$548.8K	n/m
NRC Health (NRC)	2025-12-31	$11.60M	-53.2%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗